BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37065597)

  • 1.
    Wang X; Hu Y; Li X; Zhu C; Chen F
    J Thorac Dis; 2023 Mar; 15(3):1247-1257. PubMed ID: 37065597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The m6A Reader YTHDC2 Suppresses Lung Adenocarcinoma Tumorigenesis by Destabilizing MRPL12.
    Sun Y; Liu Y; Wang P; Chang L; Huang J
    Mol Biotechnol; 2024 May; 66(5):1051-1061. PubMed ID: 38129673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
    Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
    Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of m
    Sun S; Han Q; Liang M; Zhang Q; Zhang J; Cao J
    Thorac Cancer; 2020 Nov; 11(11):3269-3279. PubMed ID: 32956555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of Id3 inhibits cell proliferation and induces apoptosis in A549/DDP human lung cancer cells in vitro.
    Chen F; Zhao Q; Wang S; Wang H; Li X
    Mol Med Rep; 2016 Jul; 14(1):313-8. PubMed ID: 27176047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
    Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
    Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exosome-transmitted circVMP1 facilitates the progression and cisplatin resistance of non-small cell lung cancer by targeting miR-524-5p-METTL3/SOX2 axis.
    Xie H; Yao J; Wang Y; Ni B
    Drug Deliv; 2022 Dec; 29(1):1257-1271. PubMed ID: 35467477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitor of DNA binding 3 reverses cisplatin resistance in human lung adenocarcinoma cells by regulating the PI3K/Akt pathway.
    Chen FF; Lv X; Zhao QF; Xu YZ; Song SS; Yu W; Li XJ
    Oncol Lett; 2018 Aug; 16(2):1634-1640. PubMed ID: 30008847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
    Xiao XH; He SY
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HNRNPA2B1-mediated m6A modification of FOXM1 promotes drug resistance and inhibits ferroptosis in endometrial cancer via regulation of LCN2.
    Jiang J; Zhu J; Qiu P; Ni J; Zhu W; Wang X
    Funct Integr Genomics; 2023 Dec; 24(1):3. PubMed ID: 38091112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The m6A RNA Modification Quantity and the Prognostic Effect of Reader YTHDC2 in Colorectal Cancer.
    Liu T; Tang W; Chen Y; Liu Y; Xu D; Jiang Y; Zhou S; Qin X; Ren L; Chang W; Xu J
    Clin Med Insights Oncol; 2022; 16():11795549221104441. PubMed ID: 35898390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of METTL14-mediated m
    Gong S; Wang S; Shao M
    J Mol Med (Berl); 2022 Dec; 100(12):1771-1785. PubMed ID: 36352154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of lncRNA-BLACAT1 on drug resistance of non-small cell lung cancer cells in DDP chemotherapy by regulating cyclin D1 expression.
    Ju ZS; Sun B; Bao D; Zhang XF
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9465-9472. PubMed ID: 33015788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anesthetic propofol enhances cisplatin-sensitivity of non-small cell lung cancer cells through N6-methyladenosine-dependently regulating the miR-486-5p/RAP1-NF-κB axis.
    Ling Q; Wu S; Liao X; Liu C; Chen Y
    BMC Cancer; 2022 Jul; 22(1):765. PubMed ID: 35836137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of shRNA on Cisplatin-resistant Non-small Cell Lung Cancer Cell A549 via Silencing
    He L; Du ZD; Wang Y; Meng RQ; Zhao WW
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 May; 51(3):312-319. PubMed ID: 32543135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-186-5p targeting SIX1 inhibits cisplatin resistance in non-small-cell lung cancer cells (NSCLCs).
    Liu X; Zhou X; Chen Y; Huang Y; He J; Luo H
    Neoplasma; 2020 Jan; 67(1):147-157. PubMed ID: 31686523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circ_0000079 Decoys the RNA-Binding Protein FXR1 to Interrupt Formation of the FXR1/PRCKI Complex and Decline Their Mediated Cell Invasion and Drug Resistance in NSCLC.
    Chen C; Zhang M; Zhang Y
    Cell Transplant; 2020; 29():963689720961070. PubMed ID: 32951448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circ_0030998 Restrains Cisplatin Resistance Through Mediating miR-1323/PDCD4 Axis in Non-small Cell Lung Cancer.
    Zhu C; Jiang X; Xiao H; Guan J
    Biochem Genet; 2022 Dec; 60(6):2434-2454. PubMed ID: 35460386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of Long Non-Coding RNA
    Zhan Y; Abuduwaili K; Wang X; Shen Y; Nuerlan S; Liu C
    Cancer Manag Res; 2020; 12():7725-7737. PubMed ID: 32943921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
    Cai Y; Dong ZY; Wang JY
    Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.